Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Traci Sanchez Vanhoose

Critical Care Medicine Ashland, KY Medical Doctor

NPI 1952564312 CMS profile 88813

613 23Rd St Ste G10, Ste G10, Ashland, KY 41101

Open in the dashboard

General payments

$6,014

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Traci Sanchez Vanhoose of Ashland, KY is reported in the CMS Open Payments database as having received $6,014 across 301 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Critical Care Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,036 59
2024 General $1,465 63
2023 General $1,670 75
2022 General $781 43
2021 General $602 34
2020 General $184 11
2019 General $275 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Traci Sanchez Vanhoose
  • Critical Care Medicine median
  • Middle half of Critical Care Medicine
  • National median

In program year 2025, general payments to Traci Sanchez Vanhoose were reported at $1,036. Among 2,664 Critical Care Medicine profiles paid that year, the median was $189 and the middle half received between $59 and $844.

Show as a table
Year Traci Sanchez Vanhoose Critical Care Medicine median Middle half National median
2019 $275 $149 $51–$535 $163
2020 $184 $110 $30–$325 $114
2021 $602 $125 $34–$403 $132
2022 $781 $157 $49–$582 $149
2023 $1,670 $162 $56–$621 $160
2024 $1,465 $168 $53–$634 $164
2025 $1,036 $189 $59–$844 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,182 93 payments
  2. AstraZeneca Pharmaceuticals LP $665 26 payments
  3. Grifols USA, LLC $589 23 payments
  4. Regeneron Healthcare Solutions, Inc. $396 13 payments
  5. Genentech USA, Inc. $393 17 payments
  6. Novartis Pharmaceuticals Corporation $389 19 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $365 19 payments
  8. Mylan Specialty L.P. $244 10 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $206 11 payments
  10. Genzyme Corporation $201 9 payments
  11. Other $1,385 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,002 300 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $609 60 payments
  2. Prolastin-C Liquid $589 23 payments
  3. NUCALA $396 25 payments
  4. FASENRA $382 11 payments
  5. TEZSPIRE $378 6 payments
  6. DUPIXENT $352 11 payments
  7. BREZTRI $323 7 payments
  8. YUPELRI $315 12 payments
  9. XOLAIR $269 13 payments
  10. OFEV $264 14 payments
  11. Other $2,996 147 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,909

Median for Critical Care (Intensivists): 406

Drug cost

$770,136

Median for Critical Care (Intensivists): $197,260

Branded share of claims

90.7%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 523 $445,894
Fasenra Pen Benralizumab Brand 21 $121,594
Spiriva Handihaler Tiotropium Bromide Brand 86 $57,455
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 43 $35,781
Albuterol Sulfate Hfa Albuterol Sulfate Brand 576 $18,448
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 118 $15,770
Symbicort Budesonide/Formoterol Fumarate Brand 35 $13,279
Spiriva Respimat Tiotropium Bromide Brand 17 $10,911
Breo Ellipta Fluticasone/Vilanterol Brand 20 $10,870
Incruse Ellipta Umeclidinium Bromide Brand 26 $9,084

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$25,913

Medicare's payments for the services billed

Medicare patients

230

Average age 71

Services billed

565

120 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 71%
Arthritis 60%
Ischemic heart disease 52%
Diabetes 37%
Heart failure 32%
Depression 31%
Chronic kidney disease 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $255
  • GENZYME CORPORATION $93
$348 — —
Prolastin-C Liquid
  • Grifols USA, LLC $270
$270 — —
XOLAIR
  • Genentech USA, Inc. $83
  • Novartis Pharmaceuticals Corporation $64
$147 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $126
$126 523 —
NUCALA
  • GlaxoSmithKline, LLC. $93
$93 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Critical Care Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record